About Event
Welcome to the Personalized Cancer Vaccine Summit!
With landmark trials underway with BioNTech and Moderna's personalized mRNA cancer vaccines for pancreatic cancer and melanoma respectively, new breakthrough designation with Syncromune's personalized in situ combination immunotherapy for metastatic prostate cancer, the race toward clinical and market approval is thriving!
The Personalized Cancer Vaccine Summit is the only conference that united biopharma companies working on different vaccine modalities to develop an immune-responsive personalized cancer vaccine for one goal - cure cancer!
TAKE A LOOK AT THE 2024 BROCHURE!
5 Key Benefits of Attending in 2024:
Uncover novel individualized platforms leveraging mRNA, DNA, peptide, viral vector, and dendritic cell-based cancer vaccines to effectively target tumor-specific neoantigens with insights from BionTech, Defence Therapeutics and Nouscom
Transform your personalized vaccine manufacturing strategy with improved sequencing, platform design and small-scale development with insights from Mayo Clinic, Genevation and BreakBio
Turbocharge your computational methods with machine learning, tumor analysis, and bioinformatics to identify the most effective neoantigens with insights from ROME Therapeutics, University of Waterloo and Achilles Therapeutics
Tackle multiple tumor-specific pathways with a two-pronged combination strategy to induce a strong immune response with insights from Nec Bio Therapeutics and Syncromune
Harness the latest clinical trial learnings to avoid the pitfalls and accelerate your personalized candidates towards market approval with better efficacy and safety with insights from AIVITA Biomedical, Imax and Geneos Therapeutics